



## FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

**Date:- November 07, 2024**

**To,**

**BSE Limited**

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

**BSE Script Code: 531599**

**National Stock Exchange of India Ltd.**

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

**NSE Symbol: FDC**

**Sub: Press Release on Q2 - FY 2024-25 Results.**

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and half year ended September 30, 2024.

Kindly take the same on record.

Thanking you,

Yours truly

**For FDC Limited**

**VARSH**

**ARANI**

**KATRE**

Digitally signed by  
VARSHARANI KATRE  
Date: 2024.11.07  
12:35:19 +05'30'

**Varsharani Katre**

**Company Secretary & Compliance Officer**

**M No.: FCS-8948**




**FDC Limited**

MANUFACTURES & EXPORTERS OF FOODS, DRUGS & CHEMICALS

### FDC Limited reports Q2FY25 results

Mumbai, 6<sup>th</sup> Nov 2024: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the second quarter ended 30<sup>th</sup> Sept 2024.



### Consolidated Q2FY25 FDC and H1FY25 reported

Rs. in crores	Q2FY25	Q2FY24	YoY Grw %	H1FY25	H1FY24	YoY Grw %
Operating Revenue	514	486	5.7%	1,152	1,023	12.6%
EBITDA	70	76	-8.2%	217	198	9.3%
EBITDA %	13.7%	15.7%		18.8%	19.4%	
PBT	90	93	-2.9%	253	233	8.3%
PAT	72	70	3.2%	191	180	6.4%
EPS (Rs.)	4.43	4.22	4.8%	11.74	10.84	8.3%

### Commenting on the results;

Your company has registered healthy revenue growth during H1FY25 of the current financial year backed by robust performance across all business segments except US Formulations. With no regulatory price revision permitted on the scheduled products, the company has been able to sustain the overall revenue and profitability growth with optimization of the operating expenses. Export formulation business reported de growth by 14.1% YoY for H1FY25 due to lower sales in US market. API business continues to show healthy revenue growth of 47% YoY during the second quarter and 25% YoY during H1FY25. EBITDA during Q2FY25 and H1FY25 is lower due to lower sales realization in Electral range of products in view of NLEM price revision, product mix change and higher employee costs.





**Business-wise Sales Performance**

₹ Cr	Q2FY25	YoY Grw %	H1FY25	YoY Grw %
Net Sales	514	5.7%	1,152	12.6%
India Formulations	422	8.7%	970	16.6%
US Formulations	22	-48.4%	42	-46.1%
ROW Markets	40	13.6%	83	23.4%
API Sales	29	47.1%	54	25.0%

**India Market:**

The sale of branded formulations in India for Q2FY25 was Rs. 422 crores, with a growth of 8.7% on YoY and lower by 23.2% over QoQ. For the first half, sales were at Rs. 970 crores, a healthy growth of 16.6% over the same period last year. Overall sales in the Indian market accounted for 82% of total consolidated sales for the quarter and 84% for H1FY25.

As per secondary sales data by IQVIA for the quarter ended Sept 30, 2024, the Company delivered YoY growth of 10.3% compared to the Indian Pharmaceutical Market (IPM) growth of 7.7% YoY. Electral has moved up to 18<sup>th</sup> in IPM in MAT Sep'24 as compared to 24<sup>th</sup> in the same period last year. Electral is the 1<sup>st</sup> FDC brand to achieve 500crs sales mark as per MAT Sep'24

Further, the company was the 5<sup>th</sup> fastest growing company as per MAT Sep'24 among the Top 25 companies.

**Export Formulations Market:**

Formulation Sales in the Export market were Rs. 62 crores in Q2FY25, down by 20.4% over YoY and lower by 2.3% over QoQ and accounted for 12% of total consolidated sales. For the first half sales were Rs. 125 crores, down by 14.1% over the same period last year. Primarily the lower sales are attributed due to dip in US business in view of change in the norms of API for certain products announced by USFDA which has now been revised by USFDA and company's products now meets the revised norms.

During the quarter, the Company filed one ANDA for Cefixime Powder for Oral suspension 100 mg/ 5 mL and 200 mg/ 5mL.

**API Business:**

API business showed good traction of growth momentum with sales of Rs. 29 crores in Q2FY25, up by 47.1% over YoY and up by 17.2% over QoQ and accounted for 6% of total consolidated sales. During H1FY25, the API business grew by 25% during H1FY25, registering sales of Rs. 54crs.



**ABOUT FDC LTD**

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

**Disclaimer**

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.



A handwritten signature in blue ink, appearing to be "S. S. S. S.", written in a cursive style.